Four biotech Nasdaq wannabes outline IPO plans — and don't miss Chi-Med's HKEX pitch
If the string of biotech IPO filings the Nasdaq saw on market close Friday says anything other than that the window for public fundraising remains …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
